Answers are grounded in this paper and cite their sources.
Nationwide matched-cohort analysis identifies elevated morbidity and mortality risk linked to FIB-4 levels, suggesting early intervention strategies.
FIB-4 ≥2.67 robustly identifies individuals with disproportionate systemic morbidity, elevated mortality risk, and substantial healthcare resource utilization. Beyond staging hepatic fibrosis, FIB-4 may function as a low-cost marker of multimorbidity and healthcare complexity. Its incorporation into multidisciplinary risk stratification frameworks may enable earlier detection of high-risk patients, inform preventive strategies, and support proactive population health management.
No takes yet. Share an insight, caveat, or question.
Baker et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: